Closing a financing gap

The Crossover strategy launched in April 2018, completing Sofinnova's investment platform by enabling it to invest across the life-sciences value chain, from seed stage to later-stage.

We invest across all biotech sectors, focusing on companies with game-changing science that has initial proof of concept.

CloseFundAMT
2018Sofinnova Crossover I€445 million
  • Close: 2018

    Fund: Sofinnova Crossover I

    AMT: €445 million

"Sometimes you need to have a significant stake in a company and be in the board room to really drive some of the strategy and the changes it may need."

"Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept."

"It is exciting to help companies find that next gear of growth as they bring new medicines to market.”

Companies

Fund iteration
Status
Deal lead

Join our mailing list

Keep up to date with our latest news.

Required
Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.